Skip to main
CNTB

CNTB Stock Forecast & Price Target

CNTB Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Connect Biopharma Holdings Ltd. is positioned favorably due to its innovative approach in developing rademikibart, which has demonstrated one of the largest reported improvements in FEV1 among biologics in its Phase 2 asthma study, indicating strong efficacy particularly in acute settings. The capability of rademikibart to target both acute and chronic conditions enhances its market potential, which could significantly increase the long-term value of Connect Biopharma’s shares. Furthermore, projected clinical data by the end of 2025 may further underscore the therapeutic advantages of rademikibart, contributing to an optimistic outlook for the company’s growth trajectory.

Bears say

Connect Biopharma Holdings Ltd faces significant challenges that contribute to a negative outlook on its stock. Increased competition in the market may hinder the company's ability to capture market share, leading to potential sales that fall short of expectations. Additionally, issues relating to patent disputes, challenging reimbursement landscapes, and the risk of unfavorable outcomes in ongoing clinical trials could further jeopardize the company's competitive position and revenue potential.

CNTB has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Connect Biopharma Holdings (CNTB) Forecast

Analysts have given CNTB a Strong Buy based on their latest research and market trends.

According to 3 analysts, CNTB has a Strong Buy consensus rating as of Jan 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Connect Biopharma Holdings (CNTB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.